TITLE

Patent Potential

AUTHOR(S)
Bauer, John F.
PUB. DATE
November 2009
SOURCE
Journal of Validation Technology;Autumn2009, Vol. 15 Issue 4, p46
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the concept of patenting pharmaceutical compounds with specific physical properties in the U.S. According to Article I, Section B of the Constitution, the Congress has the power to promote the progress of science by securing the exclusive right to the inventors' respective writings and discoveries. Examples of patents on physical properties of pharmaceuticals include ranitidine, terazosin, ritonavir, sirolimus and nifedipine. The ability to demonstrate infringement is an important aspect to be considered when obtaining a patent on a property.
ACCESSION #
47337023

 

Related Articles

  • Drug industry urges administration to come down on Argentinian piracy.  // Chemical Market Reporter;01/13/97, Vol. 251 Issue 2, p16 

    Reports on the pharmaceutical industry's call on US President Bill Clinton's administration to retaliate against Argentina for allowing widespread piracy of American drug patents. Estimated losses incurred by the domestic drug industry due to ineffective patent protection by the Argentinian...

  • The Case for Global Patent Protection. Ganorkar, Chaaya; Korth, Christopher // Pharmaceutical Executive;May2000, Vol. 20 Issue 5, p76 

    Addresses the concerns of pharmaceutical companies on patent infringement. Organizations that have reasons for having stronger global patent laws; Discussion on the status of patent systems around the world; Strategy for developing a standardized global patent system with stringent operating...

  • Whose Property Is It, Anyway?  // European Pharmaceutical Executive;May/Jun2006, p18 

    The article discusses the need for the pharmaceutical industry to change its attitude towards intellectual property to survive the changing climate of patent rights in Europe. It focuses on the issue of whether the possession of a single patent was sufficient grounds to bring someone else's...

  • Turning the Tables.  // InsideCounsel;Oct2011, Vol. 22 Issue 238, p18 

    The article discusses how big corporations in the U.S. are aiming to generate profits through plaintiff recovery lawsuits. Pharmaceutical and technological companies are using recovery suits to protect their intellectual property and at the same time, earning money from patent infringement....

  • IN THE NEWS.  // Review of Optometry;03/15/2001, Vol. 138 Issue 3, p4 

    Reports developments in the optometry and pharmaceutical industries in the United States as of March 2001. Patent infringement lawsuit filed by Pharmacia against Allergan; Launch a continuing education web site by SECO International; Introduction of the preferred pricing program of VSP.

  • IP for Drug Document Systems. Piper Jr., Donald R.; Umen, Michael J. // Pharmaceutical Executive;May2003, Vol. 23 Issue 5, p18 

    Reports on the patents on the electronic drug-document production system used by pharmaceutical companies in the U.S. Risk of lawsuit for patent infringement in a federal district court; Need to review the drug document production system in use; Violation to patent law.

  • Lawsuits Influence Course of Market.  // Chain Drug Review;2/12/2010, Vol. 32 Issue 4, p55 

    The article reports on the patent expiration case by Teva Pharmaceuticals Industries Ltd. for the infringement of generic drugs.

  • Statins could face generic threats.  // Drug Store News;1/17/2005, Vol. 27 Issue 1, p31 

    Reports on the impact of the Lipitor patent trial on operators in the prescription statin market in the U.S. Persistence of patent uncertainty through 2005; Increase in competition among generic drug manufacturers; Filing of patent infringement lawsuit by Pfizer.

  • ADDITIONAL DEVELOPMENTS--PATENT.  // Berkeley Technology Law Journal;Annual Review 2003, Vol. 18 Issue 1, p227 

    Reports on the decision of U.S courts on cases involving patent infringement. Effect of language found only in the preamble on the scope of a claim; Invalidation of a patent under the on-sale bar; Patent claim narrowed by representation made in the prosecution history.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics